Company: NKLR
Filing Date: 2025-10-02
Form Type: 424B3
Source: 0001213900-25-095492
Chunk: 0

Company: Terra Innovatum Global N.V.
Filing Date: 2025-10-02
Form: 424B3
Chunk 0
---
Filed Pursuant to Rule 424(b)(3)
Registration No.: 333-287271 Proxy Statement / Prospectus Supplement No. 1 To Proxy Statement / Prospectus dated September 16, 2025 SUPPLEMENT TO
PROXY STATEMENT FOR EXTRAORDINARY GENERAL MEETING OF
GSR III ACQUISITION CORP.
(A CAYMAN ISLANDS EXEMPTED COMPANY) and PROSPECTUS FOR UP TO 80,241,571 ORDINARY SHARES AND 8,040 PREFERRED
SHARES OF TERRA INNOVATUM GLOBAL S.R.L. This supplement updates information in the proxy statement/prospectus, dated September 16, 2025, included in the registration statement on Form S -4, Registration No. 333 -287271(the “ Registration Statement”), filed by Terra Innovatum Global s.r.l., an Italian limited liability company limited by shares (“ Terra Global”), Terra Innovatum s.r.l., an Italian limited liability company, and GSR III Acquisition Corp., a Cayman Islands exempted company (“ GSR III”). GSR III filed a proxy statement, in connection with the extraordinary general meeting of shareholders of GSR III scheduled to be held on October 7, 2025 (the “ General Meeting”). Specifically, this supplement provides updated information regarding the following changes: (i) the execution of subscription agreements to purchase PubCo Ordinary Shares in a private placement that will result in gross proceeds of approximately $34.6 million and the issuance of 3,461,000 additional PubCo Ordinary Shares at Closing, together with warrants to purchase an additional 2,595,750 PubCo Ordinary Shares; (ii) the execution of additional bridge financing notes in the aggregate amount of $560.0 thousand which are convertible into 80,514 PubCo Ordinary Shares, together with warrants to purchase an additional 161,028 PubCo Ordinary Shares; (iii) the determination of the committee members of PubCo’s board committees; and (iv) changes to the Terra Innovatum beneficial ownership disclosure. The proxy statement/prospectus provides detailed information about the Business Combination and other matters to be considered at the General Meeting. You are encouraged to carefully read the entire document, including the annexes. Terms not otherwise defined herein are as defined in the proxy statement/prospectus. You should, in particular, carefully consider the risk factors described in “Risk Factors” beginning on page 23 of the proxy statement/prospectus. NEITHER THE U.S. SEC